rs137852508
Orientation | minus |
Stabilized | minus |
Geno | Mag | Summary |
---|---|---|
(C;C) | 0 | common in clinvar |
Make rs137852508(C;T) |
Make rs137852508(T;T) |
Reference | GRCh38 38.1/141 |
Chromosome | X |
Position | 71108336 |
Gene | CXorf65, IL2RG |
is a | snp |
is | mentioned by |
dbSNP | rs137852508 |
dbSNP (classic) | rs137852508 |
ClinGen | rs137852508 |
ebi | rs137852508 |
HLI | rs137852508 |
Exac | rs137852508 |
Gnomad | rs137852508 |
Varsome | rs137852508 |
LitVar | rs137852508 |
Map | rs137852508 |
PheGenI | rs137852508 |
Biobank | rs137852508 |
1000 genomes | rs137852508 |
hgdp | rs137852508 |
ensembl | rs137852508 |
geneview | rs137852508 |
scholar | rs137852508 |
rs137852508 | |
pharmgkb | rs137852508 |
gwascentral | rs137852508 |
openSNP | rs137852508 |
23andMe | rs137852508 |
SNPshot | rs137852508 |
SNPdbe | rs137852508 |
MSV3d | rs137852508 |
GWAS Ctlg | rs137852508 |
Max Magnitude | 0 |
ClinVar | |
---|---|
Risk | rs137852508(T;T) |
Alt | rs137852508(T;T) |
Reference | Rs137852508(C;C) |
Significance | Pathogenic |
Disease | X-linked severe combined immunodeficiency not provided |
Variation | info |
Gene | CXorf65 IL2RG |
CLNDBN | X-linked severe combined immunodeficiency not provided |
Reversed | 1 |
HGVS | NC_000023.10:g.70328186G>A |
CLNSRC | ClinVar |
CLNACC | RCV000030058.2, RCV000255488.2, |
[PMID 7557965] Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis.
[PMID 8027558] Impairment of ligand binding and growth signaling of mutant IL-2 receptor gamma-chains in patients with X-linked severe combined immunodeficiency.
[PMID 8462096] Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans.
[PMID 8961626] IL2RGbase: a database of gamma c-chain defects causing human X-SCID.
[PMID 10784449] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
[PMID 11961146] Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.